Immunotherapy trials in first line metastatic or recurrent endometrial cancer
| Study | Design/Description |
| KEYNOTE-C93/GOG-3064/ENGOT-en15 | A Phase 3 Randomized Multicenter Study of Pembrolizumab vs Chemotherapy in Deficient Mismatch Repair Advanced or Recurrent Endometrial Cancer |
| GOG-3031/RUBY NCT03981796 | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-Paclitaxel vs Placebo Plus Carboplatin-Paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer |
| GOG-3041/DUO-E NCT04269200 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer |
| LEAP-001 NCT04865289 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) vs Chemotherapy for Endometrial Carcinoma (ENGOT-en9/MK-7902–001) |
| Attend NCT03603184 | Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer |
| NRG-GY-018 NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer |
| NRG-GY-020 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early-Stage High Intermediate Risk Endometrial Cancer |
| NRG-GY-025 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |